Lykos Therapeutics' application for MDMA-assisted therapy was declined by the FDA, marking a significant moment in psychedelic drug development, disappointing many advocates.
The FDA's recent decision highlights the hurdles psychedelic therapy faces despite growing research; however, they provided recommendations to enhance future MDMA applications.
The retraction of three papers in the journal Psychopharmacology due to unethical conduct raises concerns about the integrity of research within the MDMA-assisted therapy field.
MDMA, classified as a Schedule I drug, is believed to treat PTSD effectively when paired with talk therapy, yet it remains a controversial option.
[
Collection
]
[
|
...
]